Home    Back

 58. Hypertrophic cardiomyopathy
 [ 55 clinical trials,    70 drugs(DrugBank: 31 drugs),    31 target genes / 137 target pathways

Searched query = "Hypertrophic cardiomyopathy"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04133532November 1, 20194 November 2019Effect of Metoprolol in Post Alcohol Septal Ablation Patients With Hypertrophic CardiomyopathyEffect of Metoprolol in Post Alcohol Septal Ablation Patients With Hypertrophic CardiomyopathyHypertrophic CardiomyopathyDrug: MetoprololUniversity Hospital, MotolNot recruiting18 Years75 YearsAll50Phase 4
2NCT04129905October 21, 201928 October 2019Assessment of the Relations Between Endothelial and Venous Dysfunctions and Left Ventricular Obstruction in Genetic Hypertrophic CardiomyopathiesAssessment of the Relations Between Endothelial and Venous Dysfunctions and Left Ventricular Obstruction in Genetic Hypertrophic CardiomyopathiesHypertrophic Cardiomyopathy;Endothelial DysfunctionBiological: BNP blood sample test;Diagnostic Test: Electrocardiogram;Diagnostic Test: Holter ECG;Diagnostic Test: Echocardiography;Diagnostic Test: Air venous plethysmography;Diagnostic Test: Upper member arterial Doppler echography with analysis of FMD;Biological: Endothelial function biomarkersUniversity Hospital, BordeauxFédération Française de Cardiologie;Fondation Bordeaux Université;Amicus TherapeuticsNot recruiting18 YearsN/AAll40N/AFrance
3NCT03832660May 3, 201930 September 2019Sacubitril/Valsartan vs Lifestyle in Hypertrophic CardiomyopathyClinical and Genetic Determinants of Disease Progression and Response to Sacubitril/Valsartan vs Lifestyle (Physical Activity and Dietary Nitrate) in Patients With Hypertrophic CardiomyopathyHypertrophic CardiomyopathyBehavioral: Lifestyle;Drug: Sacubitril/ValsartanNewcastle UniversityAzienda Ospedaliero-Universitaria Careggi;University Hospital Regensburg;Institute for Cardiovascular Diseases of Vojvodina;University of BelgradeRecruiting18 Years70 YearsAll240Phase 2Germany;Italy;Serbia;United Kingdom
4EUCTR2018-000029-29-NL11/12/201828 February 2019Extra energy for hearts with a genetic defect: ENERGY trialExtra energy for hearts with a genetic defect: ENERGY trial - ENERGYHypertrophic cardiomyopathy;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]Trade Name: Vastarel
Product Name: Vastarel
Pharmaceutical Form: Capsule, soft
Pharmaceutical form of the placebo: Capsule, soft
Route of administration of the placebo: Oral use
VU University Medical CenterAuthorised Female: yes
Male: yes
40Phase 2Netherlands
5EUCTR2017-002530-23-NL10/12/201828 February 2019A study to evaluate the safety and benefit of Mavacamten (MYK 461) in adults with an inherited heart disease causing thickening of the heart muscleA Randomized, Double blind, Placebo controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy - EXPLORER-HCMHypertrophic Cardiomyopathy
MedDRA version: 20.0 Level: PT Classification code 10020871 Term: Hypertrophic cardiomyopathy System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: Mavacamten
Product Code: MYK-461
Pharmaceutical Form: Capsule
INN or Proposed INN: NA
CAS Number: NA
Current Sponsor code: MYK-461
Other descriptive name: MAVACAMTEN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2.5-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Product Name: Mavacamten
Product Code: MYK-461
Pharmaceutical Form: Capsule
INN or Proposed INN: NA
CAS Number: NA
Current Sponsor code: MYK-461
Other descriptive name: MAVACAMTEN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Product Name: Mavacamten
Product Code: MYK-461
Pharmaceutical Form: Capsule
INN or Proposed INN: NA
CAS Number: NA
Current Sponsor code: MYK-461
Other descriptive name: MAVACAMTEN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Product Name: Mavacamten
Product Code: MYK-461
Pharmaceutical Form: Capsule
INN or Proposed INN: NA
CAS Number: NA
Current Sponsor code: MYK-461
Other descriptive name: MAVACAMTEN
MyoKardia, Inc.Authorised Female: yes
Male: yes
220Phase 3United States;Portugal;Spain;Israel;United Kingdom;Italy;France;Czech Republic;Belgium;Poland;Denmark;Netherlands;Germany
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT03767855December 4, 201814 October 2019A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult SubjectsA Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multi-Part, Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult SubjectsSymptomatic Obstructive Hypertrophic Cardiomyopathy;Healthy SubjectsDrug: CK-3773274;Drug: PlaceboCytokineticsRecruiting18 Years55 YearsAll108Phase 1United States
7ChiCTR-IIR-170136612018-10-1015 October 2018Effect of beta-blockers combined with angiotensin II receptor blockers in regression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy: A multicenter randomized, controlled clinical trialEffect of beta-blockers combined with angiotensin II receptor blockers in regression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy: A multicenter randomized, controlled clinical trialHypertrophic cardiomyopathyExperimental group:Metoprolol Succinate Sustained-release Tablets combined with candesartan treatment;Control group:Metoprolol Succinate Sustained-release Tablets monotherapy;The First Affiliated Hospital, Sun Yat-sen UniversityRecruiting1865BothExperimental group:130;Control group:130;Phase 4 studyChina
8NCT03723655October 5, 201811 November 2019A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCMA Long-Term Safety Extension Study of Mavacamten (MYK-461) in Adults With Hypertrophic Cardiomyopathy Who Have Completed the MAVERICK-HCM (MYK-461-006) or EXPLORER-HCM (MYK-461-005) Trials (MAVA-LTE)Hypertrophic Cardiomyopathy;Obstructive Hypertrophic Cardiomyopathy;Non-obstructive Hypertrophic CardiomyopathyDrug: mavacamtenMyoKardia, Inc.Recruiting18 YearsN/AAll280Phase 2/Phase 3United States;Czechia;France;Germany;Italy;Poland;Portugal;Spain
9EUCTR2017-002530-23-DE04/10/201815 October 2018A study to evaluate the safety and benefit of Mavacamten (MYK 461) in adults with an inherited heart disease causing thickening of the heart muscleA Randomized, Double blind, Placebo controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy - EXPLORER-HCMHypertrophic Cardiomyopathy
MedDRA version: 20.0 Level: PT Classification code 10020871 Term: Hypertrophic cardiomyopathy System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: Mavacamten
Product Code: MYK-461
Pharmaceutical Form: Capsule
INN or Proposed INN: NA
CAS Number: NA
Current Sponsor code: MYK-461
Other descriptive name: MAVACAMTEN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2.5-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Product Name: Mavacamten
Product Code: MYK-461
Pharmaceutical Form: Capsule
INN or Proposed INN: NA
CAS Number: NA
Current Sponsor code: MYK-461
Other descriptive name: MAVACAMTEN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Product Name: Mavacamten
Product Code: MYK-461
Pharmaceutical Form: Capsule
INN or Proposed INN: NA
CAS Number: NA
Current Sponsor code: MYK-461
Other descriptive name: MAVACAMTEN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Product Name: Mavacamten
Product Code: MYK-461
Pharmaceutical Form: Capsule
INN or Proposed INN: NA
CAS Number: NA
Current Sponsor code: MYK-461
Other descriptive name: MAVACAMTEN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 15-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
MyoKardia, Inc.AuthorisedFemale: yes
Male: yes
220Phase 3United States;Portugal;Spain;Israel;United Kingdom;Italy;France;Czech Republic;Belgium;Poland;Denmark;Germany;Netherlands
10EUCTR2017-002530-23-ES19/09/20181 October 2018A study to evaluate the safety and benefit of Mavacamten (MYK-461) in adults with an inherited heart disease causing thickening of the heart muscleA Randomized, Double blind, Placebo controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy - EXPLORER-HCMHypertrophic Cardiomyopathy
MedDRA version: 20.0 Level: PT Classification code 10020871 Term: Hypertrophic cardiomyopathy System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: Mavacamten
Product Code: MYK-461
Pharmaceutical Form: Capsule
INN or Proposed INN: NA
CAS Number: NA
Current Sponsor code: MYK-461
Other descriptive name: MAVACAMTEN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2.5-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Product Name: Mavacamten
Product Code: MYK-461
Pharmaceutical Form: Capsule
INN or Proposed INN: NA
CAS Number: NA
Current Sponsor code: MYK-461
Other descriptive name: MAVACAMTEN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Product Name: Mavacamten
Product Code: MYK-461
Pharmaceutical Form: Capsule
INN or Proposed INN: NA
CAS Number: NA
Current Sponsor code: MYK-461
Other descriptive name: MAVACAMTEN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Product Name: Mavacamten
Product Code: MYK-461
Pharmaceutical Form: Capsule
INN or Proposed INN: NA
CAS Number: NA
Current Sponsor code: MYK-461
Other descriptive name: MAVACAMTEN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 15-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
MyoKardia, Inc.AuthorisedFemale: yes
Male: yes
220Phase 3United States;Portugal;Spain;Israel;United Kingdom;Italy;France;Czech Republic;Belgium;Poland;Denmark;Germany;Netherlands
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11EUCTR2017-002530-23-PT17/09/201830 April 2019A study to evaluate the safety and benefit of Mavacamten (MYK 461) in adults with an inherited heart disease causing thickening of the heart muscleA Randomized, Double blind, Placebo controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy - EXPLORER-HCMHypertrophic Cardiomyopathy
MedDRA version: 20.0 Level: PT Classification code 10020871 Term: Hypertrophic cardiomyopathy System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: Mavacamten
Product Code: MYK-461
Pharmaceutical Form: Capsule
INN or Proposed INN: NA
CAS Number: NA
Current Sponsor code: MYK-461
Other descriptive name: MAVACAMTEN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2.5-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Product Name: Mavacamten
Product Code: MYK-461
Pharmaceutical Form: Capsule
INN or Proposed INN: NA
CAS Number: NA
Current Sponsor code: MYK-461
Other descriptive name: MAVACAMTEN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Product Name: Mavacamten
Product Code: MYK-461
Pharmaceutical Form: Capsule
INN or Proposed INN: NA
CAS Number: NA
Current Sponsor code: MYK-461
Other descriptive name: MAVACAMTEN
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 10-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Product Name: Mavacamten
Product Code: MYK-461
Pharmaceutical Form: Capsule
INN or Proposed INN: NA
CAS Number: NA
Current Sponsor code: MYK-461
Other descriptive name: MAVACAMTEN
MyoKardia, Inc.Authorised Female: yes
Male: yes
220Phase 3Portugal;United States;Spain;Israel;United Kingdom;Italy;France;Czech Republic;Belgium;Poland;Denmark;Germany;Netherlands
12NCT03607669June 1, 201820 August 2018Manganese-Enhanced Magnetic Resonance Imaging of the MyocardiumManganese-Enhanced Magnetic Resonance Imaging: Applications in CardiomyopathyIschemic Cardiomyopathy;Dilated Cardiomyopathy;Hypertrophic CardiomyopathyOther: Mangafodipir trisodiumUniversity of EdinburghRecruiting18 Years65 YearsAll90Phase 2/Phase 3United Kingdom
13NCT03470545May 29, 201811 November 2019Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic CardiomyopathyA Randomized, Double Blind, Placebo Controlled Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic CardiomyopathyObstructive Hypertrophic CardiomyopathyDrug: mavacamten;Drug: PlaceboMyoKardia, Inc.Not recruiting18 YearsN/AAll220Phase 3United States;Belgium;Czechia;Denmark;France;Germany;Israel;Italy;Netherlands;Poland;Portugal;Spain;United Kingdom
14NCT02948998May 14, 201811 June 2018Evaluating the Effect of Spironolactone on Hypertrophic CardiomyopathyEvaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy-- a Multicenter Randomized Control TrialHypertrophic Cardiomyopathy;FibrosisDrug: SpironolactoneXinhua Hospital, Shanghai Jiao Tong University School of MedicineRuijin Hospital;RenJi Hospital;Shanghai Jiao Tong University Affiliated Sixth People’s HospitalNot recruiting18 Years75 YearsAll260Phase 4China
15NCT03057002May 1, 201821 January 2019UTSW HP [13-C] Pyruvate Injection in HCMDetection of Regional Myocardial Metabolic Changes in Patients With Hypertrophic Cardiomyopathy Using Hyperpolarized Carbon 13 Magnetic Resonance Spectroscopic Imaging (MRSI)Cardiomyopathy, HypertrophicDrug: Hyperpolarized 13C-PyruvateUniversity of Texas Southwestern Medical CenterRecruiting18 Years60 YearsAll10Phase 2United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT03532802May 1, 201811 June 2018The Effect of Metoprolol in Patients With Hypertrophic Obstructive Cardiomyopathy.The Effect of Metoprolol on Myocardial Function, Perfusion, Hemodynamics and Heart Failure Symptoms in Patients With Hypertrophic Obstructive Cardiomyopathy.Hypertrophic CardiomyopathyDrug: Metoprolol Succinate;Drug: Placebo oral capsuleSteen Hvitfeldt PoulsenRecruiting18 YearsN/AAll32Phase 2Denmark
17NCT03496168April 26, 201818 March 2019Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEERAn Open-Label Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in Study MYK-461-004 (PIONEER)Hypertrophic CardiomyopathyDrug: mavacamtenMyoKardia, Inc.Not recruiting18 YearsN/AAll12Phase 2United States
18NCT03442764March 30, 201820 May 2019A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)A Randomized, Double-blind, Placebo-controlled, Concentration-guided, Exploratory Study of Mavacameten in Patients With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) and Preserved Left Ventricular Ejection FractionNon-obstructive Hypertrophic CardiomyopathyDrug: mavacamten;Drug: PlaceboMyoKardia, Inc.Not recruiting18 YearsN/AAll60Phase 2United States
19NCT03251287November 201716 December 2017Nitrite in Hypertrophic Cardiomyopathy (HCM) StudyMechanistic Study of the Effect of Inorganic Sodium Nitrate on Cardiac and Skeletal Muscle Metabolic Efficiency in Patients With Hypertrophic CardiomyopathyCardiomyopathy, HypertrophicDrug: Sodium Nitrate;Drug: Placebo;Diagnostic Test: Phosphorous Magnetic Resonance Spectroscopy;Diagnostic Test: Exercise Stress Transthoracic EchocardiogramUniversity of East AngliaNorfolk and Norwich University Hospitals NHS Foundation Trust;British Medical Research CouncilRecruiting18 Years80 YearsAll18Phase 1United Kingdom
20NCT03249272September 5, 201719 November 2018Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow ReserveMicrovascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow ReserveHypertrophic Cardiomyopathy;Non-ischemic Dilated Cardiomyopathy;Microvascular Ischaemia of MyocardiumDrug: Regadenoson;Drug: AdenosineDuke UniversityRecruiting18 YearsN/AAll75Phase 4United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
21NCT03259113August 16, 201716 December 2017Insertable Cardiac Monitors in Hypertrophic CardiomyopathyEvaLuation Using Cardiac Insertable Devices And TelephonE in Hypertrophic CardioMyopathyHypertrophic CardiomyopathyDevice: Insertable cardiac monitorRegion GävleborgSt. Jude Medical;Norrlands University HospitalRecruiting18 Years65 YearsAll30N/ASweden
22NCT03953989October 201627 May 2019Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic CardiomyopathyA Pilot Study Assessing the Effects of Ranolazine on Coronary Microvascular Dysfunction in Patients With Hypertrophic CardiomyopathyHCM - Hypertrophic Non-Obstructive CardiomyopathyDrug: Ranolazine PR (prolonged-release) 500 mg 1 tablet bis in die and 750 mg 1 tablet bis in dieIRCCS San RaffaeleMenarini International Operations Luxembourg SARecruiting18 Years80 YearsAll26Phase 2Italy
23NCT02862600August 1, 201616 December 2017Open-Label Study of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart FailureA Phase 2, Multi-Center, Open-Label, Ascending Dose Study on the Efficacy, Safety and Tolerability of Perhexiline in Patients With Hypertrophic Cardiomyopathy and Moderate to Severe Heart Failure With Preserved Left Ventricular FunctionCardiomyopathy, Hypertrophic;Cardiomyopathy, Hypertrophic, FamilialDrug: Perhexiline;Device: Use of bioanalytical assay to monitor plasma levels of perhexilineHeart Metabolics LimitedNot recruiting18 YearsN/AAll35Phase 2United States
24NCT02842242August 201629 April 2019A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract ObstructionA Phase 2 Open-label Pilot Study to Evaluate Efficacy, Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract ObstructionCardiomyopathy, Hypertrophic Obstructive;Left Ventricular Outflow Tract ObstructionDrug: MYK-461MyoKardia, Inc.Not recruiting18 Years70 YearsAll21Phase 2United States
25EUCTR2015-002283-16-DK08/03/20168 August 2016An international study of the effect of Valsartan in hypertrophic cardiomyopathy.Phase II randomized, placebo-controlled, double blind clinical trial of valsartan for attenuating disease evolution in early sarcomeric HCM - VANISHHypertrophic cardiomyopathy
MedDRA version: 19.0 Level: LLT Classification code 10020204 Term: HOCM Hypertrophic obstructive cardiomyopathy System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Trade Name: Diovan 40 mg
Pharmaceutical Form: Coated tablet
INN or Proposed INN: VALSARTAN
CAS Number: 137862-53-4
Current Sponsor code: Diovan
Other descriptive name: Diovan
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 40-
Pharmaceutical form of the placebo: Coated tablet
Route of administration of the placebo: Oral use
Trade Name: Diovan 80 mg
Pharmaceutical Form: Coated tablet
INN or Proposed INN: VALSARTAN
CAS Number: 137862-53-4
Current Sponsor code: Diovan
Other descriptive name: Diovan
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 80-
Pharmaceutical form of the placebo: Coated tablet
Route of administration of the placebo: Oral use
Trade Name: Diovan 160 mg
Pharmaceutical Form: Coated tablet
INN or Proposed INN: VALSARTAN
CAS Number: 137862-53-4
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 160-
Pharmaceutical form of the placebo: Coated tablet
Route of administration of the placebo: Oral use
National Heart, Lung, and Blood Institute / National Institutes of HealthAuthorisedFemale: yes
Male: yes
150Phase 2Denmark
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
26NCT02560467December 1, 201517 June 2019Perfusion Imaging With Myocardial Contrast Echocardiography in HCMHypertrophic CardiomyopathyDrug: Echo and myocardial contrast echocardiography perfusion imagingOregon Health and Science UniversityNot recruiting19 Years80 YearsAll10N/AUnited States
27EUCTR2015-003521-34-FR09/10/20157 December 2015Hypertrophic CARdiomyopathy symptom release by alpha stimulant MIDOdrineHypertrophic CARdiomyopathy symptom release by alpha stimulant MIDOdrine - Light-CARMIDOHypertrophic cardiomyopathy;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]Trade Name: Gutron 2,5mg
Pharmaceutical Form: Capsule
INN or Proposed INN: MIDODRINE HYDROCHLORIDE
CAS Number: 3092-17-9
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 2.5-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
Trade Name: Gutron 5mg
Pharmaceutical Form: Capsule
INN or Proposed INN: MIDODRINE HYDROCHLORIDE
CAS Number: 3092-17-9
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
CHU de BordeauxAuthorisedFemale: yes
Male: yes
France
28NCT02590809October 7, 201516 December 2017Hypertrophic Cardiomyopathy Symptom Release by BX1514MHypertrophic CardiomyopathyDrug: Treatment BX1514M;Drug: Placebo;Other: Walk distance test;Other: Exercise echocardiographyUniversity Hospital, BordeauxNot recruiting18 Years80 YearsAll38Phase 2France
29NCT02431221July 22, 201516 December 2017Efficacy, Safety, and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart FailureA Study on the Efficacy, Safety, and Tolerability of Perhexiline Maleate in Subjects With Hypertrophic Cardiomyopathy and Moderate-To-Severe Heart FailureHypertrophic CardiomyopathyDrug: Perhexiline;Drug: PlaceboHeart Metabolics LimitedNot recruiting18 YearsN/AAll0Phase 3
30NCT02559726June 20154 July 2016Hyper-synchronicity in Hypertrophic Cardiomyopathy (HCM) : Description, Mechanism and Origin With a Multi-imaging Approach to Predict Dual Chamber Pacing ResponseIdentification and Quantification of a Mechanical Hyper-synchronicity State in Hypertrophic Cardiomyopathy (HCM) With Left Outflow-tract Obstruction and Description of Its Electrical and Electro-mechanical Characteristics Thanks to an Innovative Multi-imaging Approach to Predict a Positive Response to Dual Chamber Pacing. The Hsync Study.Hypertrophic Cardiomyopathy;Mechanical Hyper-synchronicityProcedure: Echocardiography (TEE);Device: Magnetic resonance imaging (MRI) with gadolinium enhancement;Device: Magnetic resonance imaging (MRI) without gadolinium enhancement;Procedure: 3D electrocardiographic mapping (ECM)University Hospital, BordeauxRecruiting18 YearsN/ABoth60N/AFrance
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
31EUCTR2013-004429-97-GB24/03/20153 April 2017A clinical trial with GS-6615 for treatment of Symptomatic Hypertrophic CardiomyopathyA Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects with Symptomatic Hypertrophic CardiomyopathySubjects with symptoms (NYHA Class = II dyspnea or CCS Class = II angina) due to hypertrophic cardiomyopathy (defined by standard criteria as a maximal LV wall thickness of = 15 mm in the absence of other causative loading abnormalities capable of producing the magnitude of hypertrophy observed)
MedDRA version: 19.0 Level: PT Classification code 10020871 Term: Hypertrophic cardiomyopathy System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Name: GS-6615 3 mg White
Product Code: GS-6615 3 mg White
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: No INN or proposed INN available
CAS Number: 1443211-72-0
Current Sponsor code: GS-6615
Other descriptive name: CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4-(trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 3-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Product Name: GS-6615 6 mg White
Product Code: GS-6615 6 mg White
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: No INN or proposed INN available
CAS Number: 1443211-72-0
Current Sponsor code: GS-6615
Other descriptive name: CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4-(trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4-(trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 6-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Product Name: GS-6615 3 mg Pink
Product Code: GS-6615 3 mg Pink
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: No INN or proposed INN available
CAS Number: 1443211-72-0
Current Sponsor code: GS-6615
Other descriptive name: CAS Name: 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-[4- (trifluoromethoxy)phenyl] IUPAC Name: 4-(Pyrimidin-2-ylmethyl)-7-[4- (trifluoromethoxy)phenyl]-3,4-dihydro-1,4-benzoxazepin-5(2H)-one
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 3-
Gilead Sciences, Inc.Not RecruitingFemale: yes
Male: yes
180Phase 2France;United States;Australia;Israel;Netherlands;Germany;Italy;United Kingdom
32NCT02329184December 201426 September 2016Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-461Safety, Tolerability, Preliminary Pharmacokinetics and Pharmacodynamics of Single Ascending Oral Doses of MYK-461 in Patient Volunteers With Hypertrophic CardiomyopathyHypertrophic CardiomyopathyDrug: MYK-461MyoKardia, Inc.Not recruiting18 Years65 YearsBoth15Phase 1United States
33EUCTR2014-001577-13-GB15/07/201428 February 2019Trientine in Hypertrophic CardiomyopathyCopper Chelation in Hypertrophic Cardiomyopathy: Open-label pilot study of Trientine in patients with hypertrophic cardiomyopathy - Copper (II) Chelation therapy in the treatment of HCMHypertrophic Cardiomyopathy
MedDRA version: 20.0 Level: PT Classification code 10020871 Term: Hypertrophic cardiomyopathy System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Trade Name: Trientine dihydrochloride
Product Name: Trientine dihydrochloride
Pharmaceutical Form: Capsule, hard
INN or Proposed INN: Trientine Dihydrochloride
CAS Number: 38260-01-4
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 300-
Manchester University NHS Foundation TrustNot Recruiting Female: yes
Male: yes
20Phase 4United Kingdom
34NCT01912534April 201429 April 2019Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCMValsartan for Attenuating Disease Evolution In Early Sarcomeric HCMHypertrophic CardiomyopathyDrug: Valsartan;Drug: PlaceboNew England Research InstitutesNational Heart, Lung, and Blood Institute (NHLBI)Not recruiting8 Years45 YearsAll211Phase 2United States;Canada
35NCT01904396August 201319 February 2015Identification of Carnitine-Responsive CardiomyopathyIdentification of Carnitine-responsive Cardiomyopathy and Myopathy in Adult Patients With Dilated and/or Hypertrophic Cardiomyopathy and Limb Girdle Weakness.Carnitine DeficiencyDrug: CarnitineUniversity Health Network, TorontoThe Physicians' Services Incorporated FoundationNot recruiting18 YearsN/ABoth30Phase 4Canada
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
36NCT01721967November 201216 December 2017Ranolazine for the Treatment of Chest Pain in HCM PatientsRanolazine for the Treatment of Angina in Hypertrophic Cardiomyopathy InvestigationHypertrophic CardiomyopathyDrug: RanolazineDuke UniversityGilead SciencesNot recruiting18 YearsN/AAll14Phase 4United States
37NCT01696370April 201219 February 2015Trimetazidine Therapy in Hypertrophic CardiomyopathyA Phase 2b Randomised, Double Blind, Placebo-controlled Trial of Trimetazidine Therapy in Patients With Non-obstructive Hypertrophic CardiomyopathyHypertrophic CardiomyopathyDrug: Trimetazidine;Other: Placebo capsuleUniversity College, LondonBritish Heart FoundationRecruiting18 YearsN/ABoth90Phase 2United Kingdom
38EUCTR2011-003392-10-GB23/01/201219 March 2012A study to look at the effect of the study drug on heart muscle thickness, the amount of drug that ends up in the blood, and the safety and tolerability of study drug in Noonan syndrome patients.An open label study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of MEK162 in Noonan syndrome hypertrophic cardiomyopathy.Noonan syndrome hypertrophic cardiomyopathy
MedDRA version: 14.1 Level: PT Classification code 10029748 Term: Noonan syndrome System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 14.1 Level: PT Classification code 10020871 Term: Hypertrophic cardiomyopathy System Organ Class: 10007541 - Cardiac disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Product Code: MEK162
Pharmaceutical Form: Film-coated tablet
CAS Number: 606143-89-9
Current Sponsor code: MEK162
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 15-
Novartis Pharma Services AGAuthorisedFemale: yes
Male: yes
22United Kingdom;United States
39EUCTR2011-004507-20-ES19/01/201216 February 2015SHMCRANOLAZINE IN PATIENTS WITH SYMPTOMATIC HYPERTROPHIC CARDIOMYOPATHY: A PILOT STUDY ASSESSING THE EFFECTS ON EXERCISE CAPACITY, DIASTOLIC FUNCTION AND SYMPTOMATIC STATUSsymptomatic hypertrophic cardiomyopathy (SHCM)
MedDRA version: 14.0 Level: PT Classification code 10020871 Term: Hypertrophic cardiomyopathy System Organ Class: 10007541 - Cardiac disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Trade Name: Ranexa
Product Code: Ranolazine 500 mg PR tablets
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: RANOLAZINE
CAS Number: 95635-55-5
Current Sponsor code: Ranolazine PR
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 500-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Trade Name: Ranexa
Product Name: Ranolazine 750 mg PR tablets
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: RANOLAZINE
CAS Number: 95635-55-5
Current Sponsor code: Ranolazine PR
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 750-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Trade Name: Ranexa
Product Name: Ranolazine 1000 mg PR tablets
Pharmaceutical Form: Film-coated tablet
INN or Proposed INN: RANOLAZINE
CAS Number: 95635-55-5
Current Sponsor code: Ranolazine PR
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 1000-
Pharmaceutical form of the placebo: Film-coated tablet
Route of administration of the placebo: Oral use
Menarini International Operations Luxembourg S.A.Not RecruitingFemale: yes
Male: yes
100Spain;Germany;Italy
40NCT01537926January 201216 December 2017Hypertrophic Regression With N-Acetylcysteine in HCMPilot Feasibility Study With N-acetylcystein (NAC) in Patients With HCM Caused by Sarcomere Proteins MutationsHypertrophic CardiomyopathyDrug: N-acetylcysteine;Drug: PlaceboThe University of Texas Health Science Center, HoustonNational Institutes of Health (NIH)Not recruiting18 YearsN/AAll42Phase 1United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
41EUCTR2011-001191-19-DK26/10/20117 September 2015Effects on the heart in patients with hypertophic cardiomyopathy when treated with losartan.Cardiac effects of inhibition of the renin angiotensin system with losartan in patients with hypertrophic cardiomyopathy.Hypertrophic cardiomyopathy
MedDRA version: 14.0 Level: LLT Classification code 10020876 Term: Hypertrophic obstructive cardiomyopathy System Organ Class: 10007541 - Cardiac disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Trade Name: Losartan Bluefish 50 mg
Product Name: Losartan
Pharmaceutical Form: Tablet
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
Hjertemedicinsk klinik B, 2142, RigshospitaletNot RecruitingFemale: yes
Male: yes
Denmark
42EUCTR2011-000038-12-GB13/09/20114 August 2015Trimetazidine therapy in Hypertrophic CardiomyopathyA Phase 2b randomised, double blind, placebo-controlled trial of trimetazidine therapy in patients with non-obstructive hypertrophic cardiomyopathy. - Trimetazidine therapy in hypertrophic cardiomyopathyHypertrophic cardiomyopathy (non-obstructive)
MedDRA version: 16.1 Level: PT Classification code 10020871 Term: Hypertrophic cardiomyopathy System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Trade Name: Vastarel 20mg film coated tablets
Product Name: Trimetazidine Dihydrochloride 20mg
Product Code: not applicable
Pharmaceutical Form: Tablet
INN or Proposed INN: trimetazidine dihydrochloride
CAS Number: 13171-25-0
Current Sponsor code: not applicable
Other descriptive name: 1-(2,3,4-Trimethoxybenzyl)piperazine dihydrochloride
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
Pharmaceutical form of the placebo: Capsule
Route of administration of the placebo: Oral use
University College London (UCL)Not RecruitingFemale: yes
Male: yes
Phase 2bUnited Kingdom
43NCT01375335June 201119 February 2015The Effects of Dobutamine on Postoperative Cardiac Function in Aortic Valve ReplacementThe Effects of Dobutamine on Postoperative Systolic Deformation and Diastolic Function in Patients With Hypertrophic Cardiomyopathy Operated for Aortic Valve StenosisHeart FailureDrug: DobutamineUniversity of AarhusNot recruiting19 Years90 YearsBoth10Phase 4Denmark
44NCT00821353January 200919 February 2015Antiarrhythmic Therapy Versus Catheter Ablation for Atrial Fibrillation in Hypertrophic CardiomyopathySinus Rhythm Maintenance in Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation - Randomized Comparison of Antiarrhythmic Therapy vs. Radiofrequency Catheter Ablation (SHAARC)Atrial Fibrillation;Hypertrophic CardiomyopathyProcedure: RF catheter ablation;Drug: Antiarrhythmic drugsInstitute of Cardiology, Warsaw, PolandNot recruiting18 Years70 YearsBoth90Phase 3Poland
45NCT00879060November 200719 February 2015Clinical and Therapeutic Implications of Fibrosis in Hypertrophic CardiomyopathyClinical and Therapeutic Implications of Fibrosis in HypertrophicMyocardial Fibrosis;Hypertrophic CardiomyopathyDrug: spironolactoneTufts Medical CenterRecruiting18 Years70 YearsBoth95Phase 4United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
46NCT00317967April 200719 February 2015Study to Determine if Atorvastatin Reduces Size and Stiffness of Muscle in the Left Ventricle of the HeartStatin Induced Regression of Cardiomyopathy Trial - SirCatHypertrophic CardiomyopathyDrug: Atorvastatin;Drug: PlaceboUniversity of CalgaryHeart and Stroke Foundation of CanadaNot recruiting18 YearsN/ABoth22Phase 3Canada
47NCT00430833March 200719 February 2015CHANCE - Candesartan in Hypertrophic CardiomyopathyCandesartan Use in Hypertrophic and Non-Obstructive Cardiomyopathy Estate (The CHANCE): a Double-Blind, Placebo-Controlled, Randomized, Multicenter StudyHypertrophic CardiomyopathyDrug: candesartanCharles University, Czech RepublicAstraZenecaNot recruiting18 YearsN/ABothPhase 2Czech Republic
48NCT01150461February 200719 October 2017Effect of Losartan in Patients With Nonobstructive Hypertrophic CardiomyopathyEffect of Losartan in Patients With Nonobstructive Hypertrophic CardiomyopathyHypertrophic CardiomyopathyDrug: losartan;Drug: placeboMassachusetts General HospitalNot recruiting18 YearsN/AAll20Phase 2United States
49NCT00500552December 200619 February 2015Perhexiline Therapy in Patients With Hypertrophic CardiomyopathyMetabolic Alteration With Perhexiline Therapy in Patients With Hypertrophic Cardiomyopathy (METAL-HCM Study)Hypertrophic CardiomyopathyDrug: Perhexiline/PlaceboUniversity Hospital BirminghamBritish Heart Foundation;University College London Hospitals;University of OxfordNot recruiting18 Years80 YearsBoth44Phase 2United Kingdom
50NCT00319982January 200619 October 2017Treatment of Preclinical Hypertrophic Cardiomyopathy With DiltiazemTreatment of Preclinical Hypertrophic Cardiomyopathy With DiltiazemHypertrophic CardiomyopathyDrug: Diltiazem;Drug: PlaceboBrigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI);Boston Children’s HospitalNot recruiting5 Years39 YearsAll39Phase 2/Phase 3United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
51EUCTR2005-000755-15-GB25/10/200519 March 2012Perhexiline therapy in patients with Hypertrophic CardiomyopathyPerhexiline therapy in patients with Hypertrophic CardiomyopathyHypertrophic CardiomyopathyProduct Name: Pexsig
Pharmaceutical Form: Tablet
INN or Proposed INN: Perxexiline
CAS Number: 6724-53-4
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 100-
Pharmaceutical form of the placebo: Tablet
Route of administration of the placebo: Oral use
University Hospital of Birmingham Foundation TrustAuthorisedFemale: yes
Male: yes
50United Kingdom
52NCT00035386April 200219 February 2015Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot StudyTrans-Right Ventricular Approach to Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Feasibility StudyHypertrophic CardiomyopathyProcedure: trans-right ventricular alcohol septal ablation (TRVASA)National Heart, Lung, and Blood Institute (NHLBI)Not recruitingN/AN/ABoth12Phase 2United States
53NCT00011076February 200119 February 2015Pirfenidone to Treat Hypertrophic CardiomyopathyDouble-Blind Placebo-Controlled Study of Pirfenidone, A Novel Anti-Fibrotic Drug in Symptomatic Patients With Hypertrophic Cardiomyopathy (HCM) Associated With Left Ventricular Diastolic FunctionHypertrophic CardiomyopathyDrug: PirfenidoneNational Heart, Lung, and Blood Institute (NHLBI)Not recruitingN/AN/ABoth50Phase 2United States
54NCT00001965December 199919 February 2015Cyclosporine A to Treat Hypertrophic Cardiomyopathy (HCM)Double Blind Placebo Controlled Study of Cyclosporin A in Patients With Left Ventricular Hypertrophy Caused by Sarcomeric Gene MutationsCardiomyopathy, Hypertrophic;Heart HypertrophyDrug: Cyclosporine ANational Heart, Lung, and Blood Institute (NHLBI)Not recruitingN/AN/ABoth32Phase 2United States
55NCT00001534September 199619 February 2015Long Term Effects of Enalapril and Losartan on Genetic Heart DiseaseDouble-Blind, Placebo-Controlled Study of the Long Term Effects of Angiotensin Converting Enzyme Inhibition (Enalapril) and Angiotensin II Receptor Blockade (Losartan) on Genetically-Induced Left Ventricular Hypertrophy in Non-Obstructive HCMHypertrophic Cardiomyopathy;Left Ventricular Hypertrophy;Myocardial IschemiaDrug: LosartanNational Heart, Lung, and Blood Institute (NHLBI)Not recruitingN/AN/ABoth112N/AUnited States

Back to top